Clinical Trial Update: Efficacy and Safety of Inhaled Molgramostim (rhGM-CSF) in Autoimmune Pulmonary Alveolar Proteinosis [Phase 2]

View source ↗

Summary

Phase 2 trial update on inhaled molgramostim (rhGM-CSF) for autoimmune pulmonary alveolar proteinosis reports efficacy and safety data.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autoimmune Pulmonary Alveolar Proteinosis

Drugs mentioned

• Molgramostim (granulocyte-macrophage colony-stimulating factor (GM-CSF))

Snippet

Sponsor: Savara Inc. | Conditions: Autoimmune Pulmonary Alveolar Proteinosis | Phase 2 | Status: COMPLETED | Results posted: 2022-04-15